<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://peptidesagora.com/news/082826-fda-telehealth-glp1-marketing-warning-letters</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-28T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[FDA Slaps 30 Telehealth Firms with Warning Letters Over Compounded GLP-1 Marketing]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/fda-telehealth-glp1-marketing-warning-letters.jpg</image:loc>
      <image:title><![CDATA[FDA Slaps 30 Telehealth Firms with Warning Letters Over Compounded GLP-1 Marketing]]></image:title>
      <image:caption><![CDATA[FDA Commissioner Marty Makary called it a new era of enforcement. Thirty telehealth companies received warning letters for marketing compounded GLP-1 drugs as equivalent to Ozempic and Mounjaro, with 15 business days to correct violations.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/082826-samsung-biologics-polypeptide-acquisition-2-2b</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-28T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Samsung Biologics Approves $2.2B Rights Offering to Fund PolyPeptide Deal]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/samsung-biologics-polypeptide-acquisition-2-2b.jpg</image:loc>
      <image:title><![CDATA[Samsung Biologics Approves $2.2B Rights Offering to Fund PolyPeptide Deal]]></image:title>
      <image:caption><![CDATA[Samsung Biologics voted August 28 to raise 3 trillion won through a rights offering, dedicating most proceeds to its record PolyPeptide Group purchase and the rest to a sixth plant in Incheon. Shares fell on dilution concerns.]]></image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://peptidesagora.com/news/082826-samsung-biologics-polypeptide-acquisition-funding</loc>
    <news:news>
      <news:publication>
        <news:name>Peptides Agora</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-08-28T18:00:00.000Z</news:publication_date>
      <news:title><![CDATA[Samsung Biologics Prices $2.2B Rights Offering to Close PolyPeptide Acquisition]]></news:title>
    </news:news>
    <image:image>
      <image:loc>https://peptidesagora.com/images/articles/samsung-biologics-polypeptide-acquisition-funding.jpg</image:loc>
      <image:title><![CDATA[Samsung Biologics Prices $2.2B Rights Offering to Close PolyPeptide Acquisition]]></image:title>
      <image:caption><![CDATA[The Aug. 28 rights offering prices 2.27 million shares at 1.322 million won each, directing 2.71 trillion won to the Swiss CDMO deal and 294.8 billion won to Bio Campus II expansion.]]></image:caption>
    </image:image>
  </url>
</urlset>